(Q34247391)

31 July 2017

title

Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection (English)

1 reference

31 July 2017

Trevor W Stone

1

0 references

author name string

Caroline M Forrest

series ordinal

2

1 reference

31 July 2017

L Gail Darlington

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

27 March 2012

1 reference

31 July 2017

1 reference

31 July 2017

volume

279

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

1386-1397

1 reference

Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Quinolinic acid, the inescapable neurotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Inhibitors of the kynurenine pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Endogenous kynurenines as targets for drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Kynurenines in the CNS: from endogenous obscurity to therapeutic importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Quinolinic acid is a potent lipid peroxidant in rat brain homogenates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Increased sensitivity to N-methyl-D-aspartate receptor-induced excitotoxicity in cerebellar granule cells from interleukin-1 receptor type I-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Adenosine receptors and neurological disease: neuroprotection and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Human microglia convert l-tryptophan into the neurotoxin quinolinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Delayed increases in regional brain quinolinic acid follow transient ischemia in the gerbil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Altered kynurenine metabolism correlates with infarct volume in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Increased kynurenic acid in the brain after neonatal asphyxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

SNAP and SIN-1 increase brain production of kynurenic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Electrochemical and in vitro evaluation of the redox-properties of kynurenine species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

3-Hydroxykynurenine and 3-Hydroxyanthranilic Acid Generate Hydrogen Peroxide and Promote α-Crystallin Cross-Linking by Metal Ion Reduction†

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Neopterin as a marker for immune system activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Presence of 3-hydroxyanthranilic acid in rat tissues and evidence for its production from anthranilic acid in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

T cell apoptosis by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Copper(II) interactions with nonsteroidal antiinflammatory agents. II. Anthranilic acid as a potential. OH-inactivating ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Copper(II) interactions with non-steroidal anti-inflammatory agents. III--3-Methoxyanthranilic acid as a potential *OH-inactivating ligand: a quantitative investigation of its copper handling role in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected rhesus macaques: relationship to clinical and viral status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Role of kynurenines in the neurotoxic actions of kainic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

The possible contribution of microglia and macrophages to delayed neuronal death after ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Temporal and spatial changes of quinolinic acid immunoreactivity in the gerbil hippocampus following transient cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

4-substituted-3-phenylquinolin-2(1H)-ones: acidic and nonacidic glycine site N-methyl-D-aspartate antagonists with in vivo activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Structure-activity relationships of 4-hydroxy-3-nitroquinolin-2(1H)-ones as novel antagonists at the glycine site of N-methyl-D-aspartate receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Modulation of Quinolinic and Kynurenic Acid Content in the Rat Brain: Effects of Endotoxins and Nicotinylalanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

(R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

4-Halo-3-hydroxyanthranilic acids: Potent competitive inhibitors of 3-hydroxy-anthranilic acid oxygenase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

Quinolinic acid: regional variations in neuronal sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2012.08487.X

10.1111/J.1742-4658.2012.08487.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference